1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer
in: 2008 GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
4
|
Yan B, Yau EX, Omar Bte SS, Ong CW, Pang
B, Yeoh KG and Salto-Tellez M: A study of HER2 gene amplification
and protein expression in gastric cancer. J Clin Pathol.
63:839–842. 2010. View Article : Google Scholar : PubMed/NCBI
|
5
|
Yamanoi K, Fukuma M, Uchida H, Kushima R,
Yamazaki K, Katai H, Kanai Y and Sakamoto M: Overexpression of
leucine-rich repeat-containing G protein-coupled receptor 5 in
gastric cancer. Pathol Int. 63:13–19. 2013. View Article : Google Scholar : PubMed/NCBI
|
6
|
Ning X, Sun S, Zhang K, Liang J, Chuai Y,
Li Y and Wang X: S100A6 protein negatively regulates
CacyBP/SIP-mediated inhibition of gastric cancer cell proliferation
and tumorigenesis. PLoS One. 7:e301852012. View Article : Google Scholar : PubMed/NCBI
|
7
|
Baek D, Villén J, Shin C, Camargo FD, Gygi
SP and Bartel DP: The impact of microRNAs on protein output.
Nature. 455:64–71. 2008. View Article : Google Scholar : PubMed/NCBI
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Chen L, Zhang W, Yan W, Han L, Zhang K,
Shi Z, Zhang J, Wang Y, Li Y, Yu S, et al: The putative tumor
suppressor miR-524-5p directly targets Jagged-1 and Hes-1 in
glioma. Carcinogenesis. 33:2276–2282. 2012. View Article : Google Scholar : PubMed/NCBI
|
10
|
Liu SM, Lu J, Lee HC, Chung FH and Ma N:
miR-524-5p suppresses the growth of oncogenic BRAF melanoma by
targeting BRAF and ERK2. Oncotarget. 5:9444–9459. 2014. View Article : Google Scholar : PubMed/NCBI
|
11
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative CT method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
12
|
Hou T, Ou J, Zhao X, Huang X, Huang Y and
Zhang Y: MicroRNA-196a promotes cervical cancer proliferation
through the regulation of FOXO1 and p27Kip1. Br J Cancer.
110:1260–1268. 2014. View Article : Google Scholar : PubMed/NCBI
|
13
|
Gao J, Ding F, Liu Q and Yao Y: Knockdown
of MACC1 expression suppressed hepatocellular carcinoma cell
migration and invasion and inhibited expression of MMP2 and MMP9.
Mol Cell Biochem. 376:21–32. 2013. View Article : Google Scholar : PubMed/NCBI
|
14
|
Liu Q, Yang P, Tu K, Zhang H, Zheng X, Yao
Y and Liu Q: TPX2 knockdown suppressed hepatocellular carcinoma
cell invasion via inactivating AKT signaling and inhibiting MMP2
and MMP9 expression. Chin J Cancer Res. 26:410–417. 2014.PubMed/NCBI
|
15
|
Huang Q, Lan F, Wang X, Yu Y, Ouyang X,
Zheng F, Han J, Lin Y, Xie Y, Xie F, et al: IL-1β-induced
activation of p38 promotes metastasis in gastric adenocarcinoma via
upregulation of AP-1/c-fos, MMP2 and MMP9. Mol Cancer. 13:182014.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
17
|
Yao Y, Suo AL, Li ZF, Liu LY, Tian T, Ni
L, Zhang WG, Nan KJ, Song TS and Huang C: MicroRNA profiling of
human gastric cancer. Mol Med Rep. 2:963–970. 2009.PubMed/NCBI
|
18
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
20
|
Zhu ED, Li N, Li BS, Li W, Zhang WJ, Mao
XH, Guo G, Zou QM and Xiao B: miR-30b, down-regulated in gastric
cancer, promotes apoptosis and suppresses tumor growth by targeting
plasminogen activator inhibitor-1. PLoS One. 9:e1060492014.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Cho WJ, Shin JM, Kim JS, Lee MR, Hong KS,
Lee JH, Koo KH, Park JW and Kim KS: miR-372 regulates cell cycle
and apoptosis of ags human gastric cancer cell line through direct
regulation of LATS2. Mol Cells. 28:521–527. 2009. View Article : Google Scholar : PubMed/NCBI
|
22
|
Feng R, Chen X, Yu Y, Su L, Yu B, Li J,
Cai Q, Yan M, Liu B and Zhu Z: miR-126 functions as a tumour
suppressor in human gastric cancer. Cancer Lett. 298:50–63. 2010.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Zhang Z, Li Z, Gao C, Chen P, Chen J, Liu
W, Xiao S and Lu H: miR-21 plays a pivotal role in gastric cancer
pathogenesis and progression. Lab Invest. 88:1358–1366. 2008.
View Article : Google Scholar : PubMed/NCBI
|
24
|
Liu SM, Lu J, Lee HC, Chung FH and Ma N:
miR-524-5p suppresses the growth of oncogenic BRAF melanoma by
targeting BRAF and ERK2. Oncotarget. 5:9444–9459. 2014. View Article : Google Scholar : PubMed/NCBI
|
25
|
Elmore S: Apoptosis: A review of
programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
|
26
|
Cotter TG: Apoptosis and cancer: The
genesis of a research field. Nat Rev Cancer. 9:501–507. 2009.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Bang YJ, Kim YW, Yang HK, Chung HC, Park
YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, et al: CLASSIC trial
investigators: Adjuvant capecitabine and oxaliplatin for gastric
cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label,
randomised controlled trial. Lancet. 379:315–321. 2012. View Article : Google Scholar : PubMed/NCBI
|
28
|
Chen K, Zhang S, Ji Y, Li J, An P, Ren H,
Liang R, Yang J and Li Z: Baicalein inhibits the invasion and
metastatic capabilities of hepatocellular carcinoma cells via
down-regulation of the ERK pathway. PLoS One. 8:e729272013.
View Article : Google Scholar : PubMed/NCBI
|
29
|
Lee SJ, Kim WJ and Moon SK: Role of the
p38 MAPK signaling pathway in mediating interleukin-28A-induced
migration of UMUC-3 cells. Int J Mol Med. 30:945–952.
2012.PubMed/NCBI
|
30
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
31
|
Seiki M: Membrane-type 1 matrix
metalloproteinase: A key enzyme for tumor invasion. Cancer Lett.
194:1–11. 2003. View Article : Google Scholar : PubMed/NCBI
|
32
|
Ueda J, Kajita M, Suenaga N, Fujii K and
Seiki M: Sequence-specific silencing of MT1-MMP expression
suppresses tumor cell migration and invasion: Importance of MT1-MMP
as a therapeutic target for invasive tumors. Oncogene.
22:8716–8722. 2003. View Article : Google Scholar : PubMed/NCBI
|
33
|
Deryugina EI and Quigley JP: Matrix
metalloproteinases and tumor metastasis. Cancer Metastasis Rev.
25:9–34. 2006. View Article : Google Scholar : PubMed/NCBI
|
34
|
Liao YL, Hu LY, Tsai KW, Wu CW, Chan WC,
Li SC, Lai CH, Ho MR, Fang WL, Huang KH and Lin WC: Transcriptional
regulation of miR-196b by ETS2 in gastric cancer cells.
Carcinogenesis. 33:760–769. 2012. View Article : Google Scholar : PubMed/NCBI
|